The Benefits of Metformin Therapy during continuous subcutaneous Insulin Infusion treatment of Type 1 diabetic Patients,
(2003) Diabetes Care — Vol. 25 (2003)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- (en) Assess the insulin-sparing effect of oral administration of metformin along with a continuous subcutaneous insulin infusion (CSII) for the treatment of type 1 diabetic patients. 62 patients (25 women and 37 men) were studied in a monocenter, randomized, double-blind placebo-controlled study, comparing metformin (850 mg b.i.d.) with placebo in association with CSII during a 6-month period. Treatment with metformin was associated with a reduction in daily insulin requirements between V0 and V6 of -4.3 ± 9.9 units (-7.8 ± 18%) compared with an increase with placebo treatment of 1.7 ± 8.3 units (2.8 ± 12.7%) (P = 0.0043). The number of hypoglycemic events (<60 mg/dl) was similar in both groups. Significant reductions of total cholesterol (P = 0.04) and LDL cholesterol (P = 0.05) were observed in patients treated with metformin. Metformin was found to be a safe insulin-sparing agent, when used in combination with CSII for the treatment of type 1 diabetes.
- Affiliations
Louvain School of Management
Citations
Meyer, L., Guerci, B., Drouin, P., Cugnardey, Lehert, P., & Bohme, P. (2003). The Benefits of Metformin Therapy during continuous subcutaneous Insulin Infusion treatment of Type 1 diabetic Patients,. Diabetes Care, 25. https://hdl.handle.net/2078.5/128548 (Original work published 2003)